GIST Treatment Algorithm: Surgery, Targeted Therapy, and Multidisciplinary Care
Primary Treatment
- Surgery (R0 resection): Goal for localized, resectable GIST. Laparoscopic/robotic approaches when feasible. Avoid tumor rupture.
- Neoadjuvant imatinib: For large or unresectable tumors to downsize and facilitate R0 resection.
Adjuvant Therapy
- Imatinib 400 mg daily for 3 years (standard) or 5 years (high-risk: tumor >10 cm, mitotic count >10/5 mm², rupture).
- Consider extended adjuvant for intermediate/high risk per NCCN/ESMO.
Advanced/Metastatic Disease
Sequential tyrosine kinase inhibitors (TKIs) based on resistance mutations:
- 1st line: Imatinib 400 mg (800 mg for KIT exon 9).
- 2nd line: Sunitinib.
- 3rd line: Regorafenib.
- 4th line: Ripretinib (broad KIT/PDGFRA inhibition) or avapritinib (PDGFRA D842V).
Radiation Therapy
Limited role: palliative for symptomatic bone/brain mets; rarely adjuvant for positive margins when re-resection not feasible.
Monitoring
- CT abdomen/pelvis every 3–6 months on TKI.
- FDG-PET for early response assessment (metabolic response precedes size change).
- Molecular profiling at progression to guide next-line TKI selection.
Multidisciplinary Team
Sarcoma-experienced surgeons, medical oncologists, radiologists, pathologists, and genetic counselors optimize outcomes in this rare malignancy.
Medical Conditions - Related Articles
- Understanding and Treating Mouth Sores: Causes & Relief
- Nasal Sprays for Post-Nasal Drip: Relief & Treatment
- Understanding Hernia Surgery: Types, Risks & Recovery
- Benzene Exposure: Symptoms, Risks & Emergency Care
- Candida Shots: Exploring Benefits and Immune System Support
- Understanding Potassium Levels: Health Impacts & Balance
- Understanding and Treating Liver Edema: Causes, Symptoms & Solutions
